EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma

Wenjing Xiong, Liru Li, Xue Hui, Yue Liu, Hongbin Li, Yue Zhang, Shu Zhao

Clinical and Translational Oncology · 2024

DOI: 10.1007/s12094-024-03438-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, 2024. Verfasst von Wenjing Xiong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Metabolic Syndrome, Rituximab. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Medical Award Foundation, Haiyan Foundation of Harbin Medical University Cancer Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Metabolic syndrome (MetS), characterized by insulin resistance, is closely associated with the prognosis of various cancer types, but has not been reported in diffuse large B-cell lymphoma (DLBCL). The aim of this study is to examine how other clinicopathological variables and the MetS influence the prognosis of DLBCL.

Methods

Clinical and pathological data were collected from 319 patients with DLBCL who were admitted to our hospital between January 2012 and December 2020. The data accessible with SPSS 27.0 enables the utilization of various statistical methods for clinical data analysis, including independent sample t test and univariate and multivariate COX regression.

Results

The presence of MetS was linked to both overall survival (OS) and progression-free survival (PFS), in addition to other clinicopathological characteristics as age, IPI score, rituximab usage, and Ki-67 expression level. This link with OS and PFS indicated a poor prognosis, as shown by survival analysis. Subsequent univariate analysis identified IPI score, Ki-67 expression level, tumor staging, rituximab usage, lactate dehydrogenase expression level, and the presence or absence of MetS as factors linked with OS and PFS. Furthermore, multivariate Cox regression analysis confirmed the independent risk factor status of IPI score, Ki-67 expression level, rituximab usage, and the presence of MetS in evaluating the prognosis of patients with DLBCL.

Conclusion

This study’s findings indicate that patients with pre-treatment MetS had a poor prognosis, with relatively shorter OS and PFS compared to those without pre-treatment MetS. Furthermore, the presence of MetS, IPI score, Ki-67 expression level, and rituximab usage were identified as independent risk factors significantly affecting the prognosis of DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseMetabolic SyndromeRituximabHumansMaleFemaleMiddle AgedPrognosisAgedAdultAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesAged, 80 and overDoxorubicinRisk FactorsKi-67 AntigenProgression-Free SurvivalL-Lactate DehydrogenaseSurvival RateNeoplasm StagingYoung AdultVincristineCyclophosphamide

Stichwörter der Autor:innen

Diffuse large B-cell lymphomaMetabolic syndromeOverall survivalProgression-free survival

Substanzen

RituximabDoxorubicinKi-67 AntigenL-Lactate DehydrogenaseVincristineCyclophosphamide

Autor:innen und Institutionen

  • Department of Clinical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China.
  • Department of Clinical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China. zhangyue010@hotmail.com.
  • Department of Clinical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China. zs_1881@163.com.

Förderung

  • Beijing Medical Award Foundation
  • Haiyan Foundation of Harbin Medical University Cancer Hospital

Zitieren

APA

Xiong, W., Li, L., Hui, X., Liu, Y., Li, H., Zhang, Y., & Zhao, S. (2024). The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-024-03438-z

Vancouver

Xiong W, Li L, Hui X, Liu Y, Li H, Zhang Y, et al. The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma. Clinical and Translational Oncology. 2024. doi:10.1007/s12094-024-03438-z

BibTeX
@article{Xiong2024,
  author = {Xiong, Wenjing and Li, Liru and Hui, Xue and Liu, Yue and Li, Hongbin and Zhang, Yue and Zhao, Shu},
  title = {The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma},
  journal = {Clinical and Translational Oncology},
  year = {2024},
  doi = {10.1007/s12094-024-03438-z}
}
Kostenlos starten →